Parabilis Medicines

Founded in 2016 and headquartered in Cambridge, US, Parabilis Medicines focuses on creating ultra-tunable peptide therapeutics.Parabilis Medicines is focused on developing a new class of ultra-tunable peptide therapeutics, primarily through its Helicon™ peptide platform. The company’s core products center around its lead drug candidate, FOG-001 (zolucatetide), which is undergoing clinical development aimed at treating a broad range of tumors. The technology behind these therapeutics enables precise modulation of molecular interactions, which is intended to address significant unmet medical needs in oncology and other serious diseases. Parabilis Medicines aims to provide solutions that have the potential for life-changing impacts on patients and their families, with innovation rooted in a research engine custom-designed to tackle previously insurmountable challenges in drug development. The company's revenue generation strategy is primarily based on partnerships and collaborations with biopharmaceutical companies and research institutions, facilitating joint efforts in clinical trials and product commercialization. Through these partnerships, the company engages in B2B transactions, wherein it licenses its technology and drug candidates to established firms, enabling access to its innovative therapies. The revenue model also includes potential milestone payments tied to the progress of clinical trials and regulatory approvals, as well as royalties on future sales of successful products. The company is focused on launching new products, although no specific release dates have been disclosed. Additionally, Parabilis aims to expand its presence in North America and Europe, targeting healthcare markets and potential collaborations with other biopharmaceutical firms to enhance its reach and impact.

1. Series F

   Jan 8, 2026

   Amount

   $305M

   Investors

   Locked